High Dose Flu Vaccine for Elderly

Moderna looks outside US for growth

FDA won’t review Moderna application for first mRNA-based flu vaccine

The decision, which shocked company officials, comes as the FDA says it will take a stricter approach to federal vaccine approvals.

· 1d

FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

· 2d

Moderna looks outside US for growth after FDA's flu shot refusal

Seeking Alpha

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to ...

News Medical

High-dose flu vaccine could protect middle-aged adults with chronic conditions

Expanding the high-dose influenza vaccine recommendation to include middle-aged adults with chronic health conditions may make economic sense and save lives, report scientists at the ...

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results